WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406595
CAS#: 1227637-23-1
Description: Tegatrabetan, also known as Tegavivint and BC2059, is an orally bioavailable and potent β-catenin inhibitor. BC2059 potently induces apoptosis as a single agent and in combination with bortezomib in multiple myeloma. BC2059 induced apoptosis in 10/10 genetically heterogeneous human myeloma cell lines (HMCL) treated with dosages ranging from 50-500nM.
MedKoo Cat#: 406595
Name: Tegatrabetan
CAS#: 1227637-23-1
Chemical Formula: C28H36N4O6S2
Exact Mass: 588.20763
Molecular Weight: 588.74
Elemental Analysis: C, 57.12; H, 6.16; N, 9.52; O, 16.31; S, 10.89
Synonym: BC2059; BC-2059; BC 2059; tegavivint; Tegatrabetan,
IUPAC/Chemical Name: (9E,10E)-2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime
InChi Key: GAPRVZKWPDRAJA-TVRZPQSBSA-N
InChi Code: InChI=1S/C28H36N4O6S2/c1-17-9-18(2)14-31(13-17)39(35,36)21-5-7-23-25(11-21)28(30-34)26-12-22(6-8-24(26)27(23)29-33)40(37,38)32-15-19(3)10-20(4)16-32/h5-8,11-12,17-20,33-34H,9-10,13-16H2,1-4H3/b29-27-,30-28+/t17-,18+,19-,20+
SMILES Code: O=S(C1=CC2=C(C=C1)/C(C3=CC=C(S(=O)(N4C[C@H](C)C[C@H](C)C4)=O)C=C3/C2=N\O)=N\O)(N5C[C@H](C)C[C@H](C)C5)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 588.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Fiskus W, Sharma S, Saha S, Shah B, Devaraj SG, Sun B, Horrigan S, Leveque C, Zu Y, Iyer S, Bhalla KN. Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia. 2014 Dec 8. doi: 10.1038/leu.2014.340. [Epub ahead of print] PubMed PMID: 25482131.
BC2059 disrupts the WNT/beta-catenin pathway in human tumor cells. In cancer cells, BC2059 potently inhibits the WNT/beta catenin pathway as measured by modulation of clinically relevant target gene expression and a specific decrease in beta catenin protein levels. The mechanism of action for BC2059 is targeted degradation of beta catenin protein in cancer cells followed by reduced expression of beta-catenin-regulated genes that are known to promote and maintain the malignant phenotype. This results in cell cycle arrest and subsequent apoptosis.
